Abuse of prescribed controlled substances—particularly opioid analgesics—and associated morbidity and mortality are a serious public health problem. The response to this crisis must include prevention, early identification, and appropriate treatment of addiction. Prescribing NPs and PAs must understand how to manage acute and chronic pain while also being attentive to signs of drug seeking and opioid misuse and abuse. The information and tools outlined in this article can equip providers to combat the opioid epidemic.

CE/CME INFORMATION
Earn credit by reading this article and successfully completing the posttest at www.mdedge.com/clinicianreviews/ce/cme/latest. Successful completion is defined as a cumulative score of at least 70% correct.

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid through March 31, 2019.

LEARNING OBJECTIVES
• Understand the basic pharmacology of opioid medications and how they affect pain.
• Apply a stepwise approach to pain management, based on the World Health Organization’s “pain ladder.”
• Communicate to patients the key educational points on the risks of opioid use.
• Identify strategies to deter or detect opioid misuse or abuse.

C ontrolled prescription drug abuse and its associated morbidity and mortality are a serious public health problem globally. In 2015, more than 29 million people worldwide misused and abused drugs, according to the United Nations Office on Drugs and Crime.1 Opioid use disorders account for approximately 70% of that estimate.

In the US, the mortality associated with this abuse has been devastating. Between 1999 and 2014, drug overdose deaths nearly tripled; in 2014 alone, there were 47,055 such fatalities, 61% of which involved opioids.2,3 Since 2000, unintentional overdose deaths from opioids have increased by 200%.3 Overdose deaths associated with natural and semisynthetic opioids (the most commonly prescribed pain relievers) increased 9% from 2013 to 2014, while those associated with synthetic opioids (fentanyl and tramadol) nearly doubled in the same period.3

Further contributing to the problem, a person addicted to prescription opioid drugs is 40 times more likely to be addicted to heroin, compared to someone who is not addicted to opioids.4 Deaths related to heroin overdose continue to dramatically increase.3
A call to action
In August 2016, former US Surgeon General Vivek Murthy, MD, sent a personal letter to more than 2.3 million health care providers, seeking their assistance in addressing the prescription opioid crisis. Murthy acknowledged the challenges providers face when attempting to strike a balance between treating a patient’s pain and reducing the risk for opioid addiction. He explained that clinicians are uniquely situated to end this crisis, and he asked providers to pledge to “turn the tide” by taking three actions:

• Become more educated about treating pain safely and effectively.
• Screen patients for opioid use disorder and make the appropriate evidence-based treatment referrals.
• Discuss and treat addiction as a chronic disorder.

To help stem the epidemic of controlled prescription drug abuse, NPs and PAs must be knowledgeable about patient safety issues, including how to identify patients at risk for opioid misuse and recognize signs of misuse or abuse. This article aims to educate providers who have prescriptive authority about the pharmacology of opioids; safe and effective prescribing of these drugs; and how to identify and manage misuse and abuse.

OVERVIEW OF PAIN
Pain, considered the fifth vital sign, is one of the more common reasons that people seek treatment from a health care provider. Pain is a personal, individual, subjective experience: It is whatever the patient says it is and exists whenever the patient says it does. Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage.

Pain is classified as acute or chronic. Acute pain is a sudden but temporary, self-limiting response to some type of bodily injury; it generally lasts less than six months. Chronic pain is often associated with prolonged diseases such as cancer, fibromyalgia, and osteoarthritis; it persists for six months or longer.

Pain can be separated into two categories: nociceptive and neuropathic. Nociceptive pain originates from peripheral or visceral nociceptors as a result of injury and comprises somatic and visceral pain. Somatic pain is caused by injury to soft tissue, connective tissue, and bone; the classic description is a sharp, well-localized discomfort. Visceral pain originates from an organ or deeper structure; it is commonly described as dull, poorly localized, and sensitive to stretch, ischemia, and inflammation.

Neuropathic pain is an abnormal processing of pain stimuli by the peripheral nervous system or central nervous system (CNS) and can result from injury or inflammation to a nerve. Neuropathic pain is usually described by patients as electric, burning, and/or shooting. Examples include pain associated with cancer, diabetic neu-
The physiologic experience of pain follows a defined set of phases. First is **transduction**, which occurs at the moment of injury or trauma; sensory nerve endings convert the noxious stimulus into a nerve impulse. Second is **transmission** of the pain impulse to the spinal column by means of chemical messengers known as **neurotransmitters**.

After the pain impulse reaches the spinal tract, it continues to the brain, at which point there is **perception**, the third step in the process. This leads to **modulation** (also known as **anti-nociception**). In this fourth step, neurons that originate in the brainstem are activated, releasing neurotransmitters that inhibit transmission of pain. Modulation occurs in several areas of the CNS and involves the neurotransmitters serotonin, norepinephrine, and endogenous opioids (eg, ß-endorphin). During modulation, the limbic nervous system provokes a response to the painful stimulus, triggering endogenous opioids to bind to opioid receptors.

## ROLE OF OPIOIDS IN PAIN MANAGEMENT

Opioids have been used to control pain for centuries. They are extracted from the opium poppy plant, *Papaver somniferum*. From the substance extracted, roughly 9% to 14% is morphine and 0.8% to 2.5% is codeine. Opioids are used to treat many symptoms and ailments, including diarrhea, moderate to severe pain, and persistent cough.

Opioids work through receptors in the CNS, including **mu**, **kappa**, and **delta** opioid receptors and the opioid-like receptor nociceptin. The principal receptors associated with pain physiology and inhibition are **mu** and **kappa**. (Morphine, the gold standard for treating severe pain, is an opioid agonist that binds to **mu** and **kappa** receptors.)

Most opioids that are used clinically bind to **mu** receptors; these drugs provide analgesia but also present the risk for adverse effects, such as decreased respiratory drive, miosis, and decreased motor function of the gastrointestinal (GI) tract, which can lead to constipation. Because **mu** receptors are located mainly in the brain and spinal cord (as well as the GI tract), opioids also produce a feeling of euphoria that can lead to dependence.

**Kappa** receptors, in contrast, are located mainly in the limbic system, diencephalic area, and spinal cord. When these receptors are activated, they can produce spinal analgesia, dyspnea, dependence, and dysphoria.

**Delta** receptors also play a role in pain management and are associated with emotional and affective components of the experience of pain. They are largely located in the brain; when activated, they can lead to spinal and supraspinal anesthesia, as well as decreased gastric motility. Delta recep-

### TABLE 1

<table>
<thead>
<tr>
<th>Medication</th>
<th>Duration of analgesia</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine, oral</td>
<td>4-6 h</td>
<td>15-60 mg every 6 h</td>
</tr>
<tr>
<td>Fentanyl, IM</td>
<td>1-2 h</td>
<td>0.05 mg-0.1 mg</td>
</tr>
<tr>
<td>Fentanyl, transdermal</td>
<td>3 d</td>
<td>25-100 µg every 72 h</td>
</tr>
<tr>
<td>Hydrocodone, oral</td>
<td>4-6 h</td>
<td>5-10 mg every 4-6 h</td>
</tr>
<tr>
<td>Hydromorphone, oral</td>
<td>4-5 h</td>
<td>1-4 mg every 4-6 h</td>
</tr>
<tr>
<td>Hydromorphone, IM, IV, and subcutaneous</td>
<td>4-5 h</td>
<td>1-4 mg every 4-6 h (all routes)</td>
</tr>
<tr>
<td>Morphine, oral</td>
<td>4-5 h</td>
<td>30 mg every 4 h</td>
</tr>
<tr>
<td>Morphine, IV</td>
<td>4-5 h</td>
<td>2-10 mg every 2-4 h</td>
</tr>
<tr>
<td>Oxycodone, oral</td>
<td>4-6 h</td>
<td>5-10 mg every 6 h</td>
</tr>
<tr>
<td>Oxycodone, oral (controlled-release)</td>
<td>8-12 h</td>
<td>10-20 mg every 12 h</td>
</tr>
</tbody>
</table>

Abbreviations: IM, intramuscular; IV, intravenous.

tors have not been studied as much as mu and kappa receptors, but it has been suggested that they play a role in psychologic dependency.

Depending on the effect that a drug has on these receptors, it can be considered a full (or pure) opioid agonist, a partial agonist, or a mixed agonist-antagonist. By binding to opioid receptors, opioid agonists provide pain relief. Health care providers often prescribe a full agonist, such as morphine, hydrocodone, codeine, or oxycodone, to treat pain. Partial agonists, such as buprenorphine and butorphanol, often decrease activity at mu receptor sites. Mixed agonist-antagonists either block or bind opioids at receptor sites. Medications that block mu and kappa receptors are considered opioid antagonists, which are used not to treat pain but rather to reverse the effect of opioids (eg, naloxone).

Table 1 lists commonly used opioids, their analgesic duration, and the standard approved dosages.

### A STEPWISE APPROACH TO PAIN MANAGEMENT

On January 1, 2018, The Joint Commission (JNC) implemented new and revised standards to ensure that all patients receive appropriate assessment and management of their pain. While these standards apply to accredited hospitals, they provide a solid framework for assessing and treating pain in any patient. JNC now requires that patients be included in the development of treatment plans, which should encompass realistic expectations and reasonable goals, and that providers promote safe opioid use by identifying and monitoring high-risk patients.

One valuable tool that can help clinicians fulfill the obligation to provide safe and effective pain management is the World Health Organization’s “pain ladder” (see Figure 1, page 45). Originally released in 1986 to address cancer pain in the pediatric population, this tool has proven validity. It has since been expanded to guide treatment of pain in other patient populations. In addition, the steps of the “pain ladder” provide useful information on the clinical examination and documentation of pain, principles of pharmacotherapeutic management, and considerations when using different analgesics.

Pain is assessed on a scale of 1 to 10, with 1 representing the least pain. Medication recommendations are as follows:

- For mild pain (ie, a score of 1-3): acetaminophen, NSAIDs, or other nonopioids.
- For moderate pain (pain score, 4-6): an opioid (eg, hydrocodone), with or without an adjunct medication.
- For severe pain (pain score, 7-10) or pain that has not responded to previous therapies: a stronger opioid (eg, morphine, hydromorphone, fentanyl), with or without an adjuvant drug.

In all cases, patients should be informed about both pharmacotherapeutic and nonpharmacotherapeutic options. The latter include hypnosis, relaxation techniques, acupuncture, physical therapy, application of heat and cold, and electroanalgesia.

Pharmacologic options at any “step” of the ladder carry the risk for adverse effects. Thus, NPs and PAs who prescribe these medications need to apprise patients of the potential harms associated with their treatment.

- **Acetaminophen.** Patients should be instructed on the safe use of acetaminophen, particularly with regard to dosing, since liver damage can occur. Patients should not take more than 4,000 mg in a 24-hour period, and each dose should not exceed 1,000 mg.

- **NSAIDs.** These drugs are often used for short-term management of mild and moderate pain. Patients should be instructed to take these agents with food to decrease GI upset. Other common adverse effects include GI bleed or perforation and renal insufficiency or failure.

- **Opioids.** Depending on which class of receptors an opioid medication targets, patients may develop any of the following: constipation, decreased GI motility, nausea, hypotension, urinary retention, euphoria, pruritus, miosis, dependence, respiratory depression, and sedation. It is important for
NPs and PAs who prescribe these medications to remain vigilant for adverse effects and complications from opioid use and to educate the patient and his/her family about possible complications.6

Patients must be instructed not to drink alcohol or take other CNS depressants while taking an opioid. They should be advised about the dangers of operating heavy equipment or engaging in other activities that require mental and physical alertness, since opioids can cause drowsiness. Among the GI effects of some opioids (nausea, vomiting) is constipation—so patients should also be educated on the need to increase fluid intake and include high-fiber foods in their diet.9

But most important of all, patients taking an opioid should be informed that there is the potential for physical dependency and abuse with these agents, and these agents should be used only for acute, severe pain.

**TABLE 2**

<table>
<thead>
<tr>
<th>Tools to Assess Risk for Opioid Misuse/Abuse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>To assess patients being considered for long-term opioid therapy</strong></td>
</tr>
<tr>
<td>The Opioid Risk Tool (ORT)17</td>
</tr>
<tr>
<td>Screener and Opioid Assessment for Patients with Pain – Revised (SOAPP-R)18</td>
</tr>
<tr>
<td>Diagnosis, Intractability, Risk and Efficacy Inventory (DIRE)19</td>
</tr>
<tr>
<td><strong>To assess for misuse once opioid treatment is initiated</strong></td>
</tr>
<tr>
<td>The Current Opioid Misuse Measure (COMM)20</td>
</tr>
<tr>
<td>Pain Assessment and Documentation Tool (PADT)21</td>
</tr>
<tr>
<td><strong>To address the potential for substance abuse generally</strong></td>
</tr>
<tr>
<td>Cutting down, Annoyance by criticism, Guilty feeling, Eye-openers (CAGE)22</td>
</tr>
<tr>
<td>CAGE-AID (CAGE adapted to include drugs)22</td>
</tr>
<tr>
<td>Drug Abuse Screening Tool (DAST-10)23</td>
</tr>
<tr>
<td>Screening, Brief Intervention, and Referral to Treatment (SBIRT)24</td>
</tr>
</tbody>
</table>

Sources: Webster and Webster. Pain Med. 200517; SOAPP®-R18; COMM™19; PADT™20; CAGE and CAGE-AID22; Skinner. Addict Behav.198223; SBIRT AUDIT.24

be aware of the potential for some patients to misuse opioids by taking them in a different way than intended, in a different quantity than prescribed, or without a prescription.13 Having prescriptive authority confers an obligation for NPs and PAs to recognize the prevalence of drug misuse and its impact on patients, families, and society.

Regrettably, there is lack of clarity in the literature about specific characteristics and demographic data that can help determine who is at risk for opioid misuse.14 For example, risk factors that have been associated with drug misuse include a personal or family history of substance abuse; younger age; and an ongoing psychiatric condition.

In contrast, Kennedy and colleagues determined that patients seeking prescription opioids for misuse or abuse tend to be older; be of Caucasian background; have a history of overdose; be receiving methadone maintenance therapy; and have been incarcerated.15 In addition, several characteristics—having moderate or extreme pain, disability, or a history of being refused pain medication—were also associated with a history of seeking prescription opioids to abuse.15

This diverse set of variables underscores the importance of obtaining and documenting a complete history from patients who are experiencing (and seeking relief of) pain; performing a thorough physical exam; and asking specific questions about the patient’s level of pain and the potential for misuse of pain medication.

Gathering this information may help identify patients at risk for opioid misuse or abuse. Furthermore, it ensures that a patient’s chronic pain is not being under-treated and that he/she is not being undeservedly labeled or judged as a drug seeker or abuser.
Tools and strategies for appropriate use of opioids

There are tools and strategies available to ensure proper use of opioids for managing chronic noncancer pain. Urine drug testing, screening tools for opioid abuse, prescription drug monitoring programs, and opioid treatment agreements should be considered for patients who require prescription opioids to treat pain.¹⁵

**Urine drug testing.** The CDC recommends that prescribing clinicians perform urine drug testing before initiating opioid therapy and at least annually afterward. It can be used to assess for prescription medications generally, controlled prescription drugs specifically, and substances of abuse.¹⁶ Urine drug testing can mitigate the risk for misuse or overdose of opioids, as well as identify patients who were prescribed an opioid but are not taking it. The prescribing provider is responsible for explaining to the patient why urine testing is being done, performing confirmatory testing, and discussing results with the patient.

**Risk-assessment tools.** A number of web-based tools help the prescribing provider assess a patient’s risk for misuse or abuse of opioids and other substances. They fall into three general categories of use: assessing patients being considered for long-term opioid therapy; assessing for misuse once opioid treatment is initiated; and addressing the potential for substance abuse generally.¹⁷-²⁴ Table 2 lists examples. Although screening tools are not 100% accurate at identifying who is a substance abuser, they do alert the provider that a potential problem exists and needs to be explored. As such, they should be considered one component of comprehensive risk assessment, monitoring, and mitigation.²⁵

**Prescription drug monitoring programs (PDMPs).** NPs and PAs must also be aware of “doctor shopping,” in which a person seeks prescriptions from multiple providers (often under false pretenses) and has them filled at multiple pharmacies. PDMPs are designed to monitor for suspected abuse, diversion, or inappropriate prescribing. These state-run electronic databases track the amount of controlled substances prescribed, dispensed, and refilled for a given patient.²⁶ This information can assist providers in identifying high-risk patients who may benefit from an early intervention program.²⁷ Once a patient is identified as having an opioid use disorder, NPs and PAs must provide appropriate referral to an evidence-based practice for treatment of abuse. It is essential to recognize that an opioid use disorder is a chronic illness and that relapses occur.

**Opioid treatment agreements.** These have been presented as a strategy to prevent prescription drug abuse; however, there is little evidence to support their effectiveness in preventing medication misuse, abuse, or diversion of opioids. In fact, research has shown that such agreements can put the patient-provider therapeutic relationship at risk for disruption, since patients may feel mistrusted or stigmatized by the suggestion that they might behave inappropriately.²⁸ The position of the American Pain Society and the American Academy of Pain Management is that patients and clinicians should have ongoing discussions about chronic opioid therapy that include

---

**FIGURE 1**

The WHO Three-step Pain Ladder

goals, expectations, risks, and alternatives to opioids.29 If a written agreement is used, it needs to address the patient’s and the clinician’s responsibilities and expectations in managing chronic pain.28

Additional resources for providers
Many other resources are available for prescribers of controlled substances. For example, the CDC has published guidelines for prescribing opioids to patients with chronic pain, with a goal of increasing patient-provider communication.16 Additional goals include improving the safety of opioid use, maintaining the effectiveness of treatment, and reducing the necessity and practice of long-term therapy.

The FDA has also published a blueprint on how opioid analogesics can be formulated to deter abuse and, thus, be safer.30 Although directed at the pharmaceutical industry—the FDA encourages manufacturers to develop abuse-deterrent mechanisms, such as physical and chemical barriers, aversion technology, and new delivery systems—the guidance may enlighten providers on how abusers can alter or manipulate oral opioids to achieve the desired effects.30

CONCLUSION
Because NPs and PAs are authorized to prescribe Schedule II-V drugs in their scope of practice, they must have knowledge of drug-seeking behaviors and drug misuse before they prescribe opioids for pain relief. They must be attentive to patients’ pain-control needs and consider how to avoid or reduce the potential for misuse and abuse. Understanding the experience of pain and how opioids modulate it, as well as using available risk-assessment strategies, will help providers offer safe, effective treatment to their patients.

Find the posttest for this activity at www.mdedge.com/clinicianreviews/cem/cme/latest

REFERENCES